US OKs American Medical's prolapse repair technology:
This article was originally published in Clinica
Executive Summary
The US FDA has given American Medical Systems the all-clear to sell its minimally invasive technology for repairing vaginal prolapse. The Apogee system, which repairs vaginal vault prolapse using graft material, is designed to improve patient outcomes compared with traditional abdominal or laparoscopic techniques, said the Minnetonka, Minnesota company. Scheduled for commercial release later this year, it will join the firm's other prolapse product, the Straight-In Sacral Colpopexy system. Over 36 million women in the US and Europe suffer from vaginal prolapse, with over six million of those cases being severe, the firm added. Because current procedures are lengthy and complex, only 350,000 surgical repairs are performed annually.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.